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Background: The World Health Organization (WHO) classification separates mastocytosis 
into distinct entities, but a robust prognostication tool is not available. 
Methods: We analyzed the prognostic relevance of clinical and laboratory parameters in 1794 
mastocytosis patients collected in the registry of the European Competence Network on 
Mastocytosis. For validation, 462 patients from the Spanish mastocytosis-network were 
examined. 
Results: The prognostic value of the WHO classification was confirmed (p<0.005). In non-
advanced mastocytosis (n=1533), age ≥60 years and alkaline phosphatase ≥100 U/L were 
additional independent prognostic variables for survival, with a hazard ratio (HR) of 12.7 and 
34.7, respectively. A new scoring system (IPSM) divided patients with non-advanced 
mastocytosis into three groups: low risk (no risk factors), intermediate-1 risk (one risk factor), 
and intermediate-2 risk (both risk factors). Overall survival (OS), progression-free survival 
(PFS), and event-free survival (EFS) differed significantly among these subgroups and between 
these subgroups and advanced systemic mastocytosis (p<0.005). In advanced mastocytosis 
(n=261), age ≥60 years (HR=2.3), tryptase ≥125 ng/ml (HR=1.6), leukocytes ≥16x109/L 
(HR=1.9), hemoglobin ≤11 g/dL (HR=1.9), platelets ≤100x109/L (HR=1.6) and skin 
involvement (HR=0.5) were prognostic variables. Based on these parameters, a separate score 
for advanced mastocytosis was established with significantly different outcomes concerning 
OS, PFS and EFS (p<0.005). The impact of both scores was confirmed in the Spanish 
validation-cohort. 
Conclusions: Using routinely applicable prognostic parameters, including age and alkaline 
phosphatase in non-advanced mastocytosis, and age, tryptase, blood counts and skin 
involvement in advanced disease, we have established a robust prognostication score ready for 





The diagnosis of mastocytosis is based on criteria provided by the World Health Organization 
(WHO) classification [1-4]. Most patients with cutaneous mastocytosis (CM), indolent 
systemic mastocytosis (ISM) and smoldering SM (SSM), have a stable clinical course and a 
normal or near normal life expectancy [5-15]. In contrast, patients suffering from advanced SM 
(AdvSM), including aggressive SM (ASM), SM with an associated hematologic neoplasm 
(SM-AHN) and mast cell leukemia (MCL) have a poor prognosis [5-15].  
During the past two decades several clinical, serological, cytomorphological, immunological 
and molecular parameters have been reported to be of prognostic significance in mastocytosis 
[16,17-26]. Several of these variables have been included in the WHO classification [1-5]. 
Other adverse prognostic variables include absence of skin lesions, multi-lineage involvement 
with KIT D816V, mutations in genes other than KIT, including SRSF2, ASXL1 or RUNX1, 
elevated serum ß2-microglobulin, and elevated alkaline phosphatase (AP) [16,17-26]. 
However, these parameters were studied in a limited number of patients and without comparing 
all potential parameters with each other in multivariate analyses. Moreover, several of these 
parameters, like molecular profiling, are not performed in all centers. Finally, the independent 
prognostic value of most variables has not been confirmed in larger patient cohorts to date. 
In this study we used the data set of the registry of the European Competence Network on 
Mastocytosis (ECNM) to determine the prognostic impact of individual disease features and 
laboratory parameters in 1794 patients with mastocytosis. Based on the WHO classification and 
the prognostic factors identified, a scoring system ready for use in daily practice was 
established. This strength and impact of this international prognostic scoring system (IPSM) 





Patients and Methods 
 
Patients´ characteristics 
Data from 2361 patients with mastocytosis seen between 1975 and 2017 in 24 centers in Europe 
and one US center (Stanford) were included in the ECNM registry (Table S3 in the 
Supplementary Appendix) [27]. Various clinical and laboratory parameters were captured at 
diagnosis and during follow up (Table S4 A-D in the Supplement). Follow up data were 
recorded in 1794 patients (median age: 46 years; range: 0.15-90), including 1006 (56.1%) ISM, 
269 (15.0%) CM, 174 (9.7%) SM-AHN, 62 (3.5%) ASM, 53 (3.0%) SSM, 23 (1.3%) MCL, 
and 2 mast cell sarcoma (MCS, 0.1%) patients (Figure S1, Table S5 and S6 in the 
Supplementary Appendix). In 205 adult patients (11.4%) typical mast cell infiltrates in the skin 
were found, but no bone marrow (BM) examination was performed. These patients were 
included as mastocytosis in the skin (MIS) and were integrated in the non-advanced SM 
category for prognostication regarding survival [28]. The median observation-time was 3.4 
years (range: 0.01-36) (Figure S2 in the Supplement). The validation cohort consisted of 462 
patients (384 ISM, 25 SM-AHN, 19 ASM, 18 CM, 11 SSM, and 5 MCL) collected in the Red 
Española de Mastocitosis (REMA; Table S7 in the Supplement). 
 
Statistical analyses  
Overall survival (OS; time from diagnosis to death), progression-free survival (PFS; time from 
diagnosis to progression) and event-free survival (EFS; time from diagnosis to progression or 
death) were analyzed according to the method of Kaplan and Meier with Mantel-Cox tests for 
group comparisons. Since MCL is an end-stage disease (no further progression can occur) and 
MIS is a provisional diagnosis for patients with skin-involvement but unknown/unavailable 
bone marrow, these two patient-groups were excluded from PFS analysis. A description of 
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statistical analyses, including univariate (likelihood ratio and Kruskal Wallis test) and 
multivariate analyses is provided in the Supplement.  
 
Development of IPSM for non-advanced and advanced mastocytosis  
Based on results obtained in multivariate analyses, we developed two prognostic scoring 
systems, one for patients with non-advanced mastocytosis (non-AdvM i.e. CM, MIS, ISM, 
SSM) and one for AdvSM where organ damage leads to reduced survival [5,6]. Details about 






Prognostic impact of the WHO classification 
The WHO classification´s prognostic significance concerning OS and PFS was confirmed in 
the total cohort of patients (p<0.005) (Figure 1). Our registry data also confirmed that the WHO 
classification defines two prognostic groups: patients with non-advanced mastocytosis and 
those with AdvSM. However, even among cases with non-AdvM, subtle but significant 
differences could be substantiated in this large data set. Likewise, patients with CM had superior 
OS compared to all other subgroups, including ISM (Figure 1A). There was no substantial 
difference in OS when comparing childhood CM (aged<18 years; n=142) and adulthood CM 
(age ≥18 years, n=127; Figure S2 in the Supplement). Survival at 10 years and median OS in 
ISM were 93.5% and 28.4 years, respectively. In CM, MIS and SSM, the 10 year survival was 
100%, 93.0% and 84.5%, respectively. The median OS was not reached in these entities. In 
ASM, MCL, SM-AHN, MCS and SM-AHN, median OS was 5.7, 1.9, 1.1, and 2.9 years, 
respectively (Figure 1A).  
The median EFS of all patients was 25.5 years (Figure S3 in the Supplement). Overall, 239 
events were recorded. As expected, CM patients had the best outcome with only 6 events 
(2.2%). More events were documented in cases with MIS (n=10; 5.0%), ISM (n=62; 6.2%), 
SSM (n=7; 13.2%) and AdvSM (n=154; 59.0%). In patients with ASM, MCL, MCS, and SM-
AHN, the median EFS was 5.0, 1.9, 1.1, and 2.7 years, respectively (p<0.005; Figure S4 in the 
Supplement). 
After exclusion of MIS and MCL cases, PFS was analyzed in 1566 patients. Progression of 
disease was observed in 88/1566 patients (5.6%), including 39/1006 patients with ISM (3.9%), 
5/53 SSM patients (9.4%), 11/62 ASM cases (17.7%) and 27/174 patients with SM-AHN 
(15.5%) (Table 1). In CM, 6/269 cases developed ISM. Overall, PFS at 10 years was 88.0% 
7 
 
(Figure 1B). Differences in PFS between the WHO cohorts were significant (p<0.005). None 
of the WHO groups reached the median PFS (Figure 1B). 
 
Proposed IPSM for Non-Advanced Mastocytosis 
Various laboratory and clinical variables, including age, blood counts, serum tryptase levels, 
lactate dehydrogenase (LDH), AP, WHO classification, organomegaly, mediator-related 
symptoms, and known allergies were analyzed by uni- and multivariate analyses. In patients 
with non-AdvM, age ≥60 years and AP ≥100 units/liter were identified as significant 
independent predictors of evolution to ´higher grade mastocytosis´ (hazard ratio=HR: 4.0 and 
2.5, respectively) and of OS (HR: 12.7 and 34.7, respectively) (Table 2). In patients with non-
AdvM, an AP ≥100 units/liter was also associated with a significantly higher rate of progression 
to a higher-grade SM (AdvSM) (Supplementary Table 8). Based on these variables, we 
established a simple prognostic scoring system (IPSM) and applied it in 1085 patients with non-
AdvM where all variables were available. Patients with non-AdvM without additional risk-
factors comprised the low-risk group (low), and those with one or two risk factors the 
intermediate-risk group 1 (int-1) and intermediate risk-group 2 (int-2), respectively. Patients 
with AdvSM (n=261) had the worst outcome.  
OS at 10 years was 98.1% in the low risk group, 87.1% in the int-1 group, 52.1% in the int-2-
risk group, and 22.0% in the AdvSM group (p<0.005) (Figures 2A). Significant differences 
were also observed in the rate of progression, with a PFS at 10 years of 96.3% in low risk 
patients, 87.1% in int-1 patients, 76.3% in int-2 patients, and 60.8% in the AdvSM group 
(Figure 2B). The significance of the score was also confirmed for OS in MIS and ISM and for 
PFS in CM, ISM, and SSM (p<0.005) (Figure S6 and S7 in the Supplementary Appendix). In 
SSM, the differences in OS were not significant (p=0.09) which may be due to the relatively 
low number of patients. The score was also of prognostic significance regarding EFS in all 




Proposed IPSM for Advanced Mastocytosis 
In patients with AdvSM, age ≥60 years (HR=2.3), tryptase ≥125ng/ml (HR=1.6), leukocytes 
≥16x109/L (HR=1.9), hemoglobin ≤11g/dL (HR=1.9) platelets ≤100x109/L (HR=1.6), and 
skin-involvement (HR=0.5) were independent prognostic variables concerning OS in 
multivariate analyses (Table 2). These parameters were employed to optimize scoring in 
AdvSM. Each risk factor with a HR >1.5 scored 1 point, and skin-involvement (HR 0.5) scored 
-1 point. By adding all risk points, 4 different risk groups were established. The score was 
applied in 231 patients with AdvSM where all variables were available. Significant differences 
were observed among the cohorts with AdvSM-1 (-1 to 0 points), AdvSM-2 (1 point), AdvSM-
3 (2 to 3 points), and AdvSM-4 (4-5 points; p<0.0005) (Figure 2C and D). The calculated OS 
of patients with AdvSM-1 was between the OS of int-1 and the OS of the int-2 risk group of 
patients with non-advanced disease (Figure 2C). The significance of the score for AdvSM was 
also confirmed for PFS and EFS, and for individual WHO entities: ASM, MCL and SM-AHN 
(p<0.005) (Figure 2D, Figure S10-13 and Table S9 in the Supplement). 
 
Validation of the IPSM in an Independent Sample-Cohort 
The IPSM was validated using a patient cohort provided by the Spanish mastocytosis network, 
REMA. Validation was performed for patients with non-AdvM and patients with AdvSM. Both 
scores showed significant results in the validation sample (non-AdvM: n=413, p<0.005; 
AdvSM: n=49, p<0.005), confirming the prognostic power and usefulness of the IPSM (Figure 







Although the WHO classification is a well-established diagnostic approach with prognostic 
impact, an advanced tool of prognostication for mastocytosis is lacking. Notably, prognosis and 
survival of patients within distinct WHO subgroups vary substantially [15,16,28]. We 
employed the largest cohort of patients ever collected, the ECNM registry data-set, with the 
aim to define new prognostic variables and to improve prognostication. Using this data set, we 
identified independent prognostic variables for patients with non-AdvM (age and AP) and 
AdvSM (tryptase, blood counts, absence of skin-involvement). Based on these parameters, we 
established a simple prognostic score system, the IPSM. The predictive value of this new score 
was confirmed in an independent validation cohort provided by the REMA.  
So far it remained unknown whether adult patients with CM have a favorable outcome 
compared to ISM. In our study, adult patients with CM were found to have the same excellent 
OS that was also recorded in childhood CM and that is clearly superior to the OS in ISM or 
MIS. We also found that patients with MIS and ISM have a similar OS, suggesting that most 
patients with MIS may indeed suffer from ISM. This observation supports the recommendation 
that a BM study should be performed in all adult patients with MIS. So far, it remains unknown 
why adult patients with CM have a better OS compared to ISM or MIS. One explanation would 
be that ISM is a more advanced disease with higher risk of progression to AdvSM. An 
alternative explanation could be the higher median age of SM patients (MIS: 41 years; ISM: 47 
years) compared to adult CM patients (36 years).  
Several clinical and laboratory parameters are known to serve as prognostic variables in 
mastocytosis [8-10,13,16-26]. In patients with non-advanced SM, AP ≥100 U/L and age ≥60 
years were the two major independent predictors of survival and were therefore employed to 
establish a simple score-system. AP has already been shown to be of prognostic value in SM in 
previous studies [16,17,29]. Moreover, an elevation in AP levels may reflect SM-mediated 
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organ damage in the bones and/or the liver [30-32]. High AP levels found in some patients with 
non-AdvM may thus indicate a clinically silent organ involvement. Such occult liver 
involvement may produce an elevated AP even before the disease progresses to AdvSM. 
Indeed, we found a significantly higher rate of progression from ISM/SSM to AdvSM in 
patients with AP ≥100 units/liter. 
Analyzing the median age in our patients, we found that age increases constantly from low (43 
years) to int-1 (53 years) and int-2 (64 years) patients. A simple explanation for this observation 
would be that reduced life expectancy is primarily due to the higher age in these patients. 
However, not only OS, but also PFS differed significantly among these patients. Thus, our 
results cannot only be explained by differences in the ´natural´ age-dependent life expectancy. 
With regard to PFS, it is tempting to speculate that an increased clonal instability at higher age 
might contribute to a higher rate of progression. Indeed, it is known that the number of 
mutations in hematopoietic (stem) cells increases with age [33,34]. 
Recently, organomegaly was found to be of prognostic significance in SM [17,29]. In the 
present study, organomegaly defined by enlarged spleen and/or liver and/or lymphadenopathy 
was not an independent prognostic factor for OS which may be explained by the fact that 
organomegaly is represented in the WHO criteria as either B-finding (without organ 
dysfunction) or as C-finding (with organ damage) [3-4].  
A number of previous studies have shown that patients with AdvSM often lack skin 
involvement [3-5]. In the present study, the absence of typical skin lesions was of prognostic 
significance in multivariate analysis in AdvSM, but not in patients with non-AdvM. This result 
has several explanations. First, it is well known that skin lesions are preferentially absent in 
patients with rapidly progressive ASM and MCL. Second, there is also a subgroup of ISM 
patients in whom no skin lesions are found and the clinical course remains stable. Contrasting 
AdvSM, these patients have a low mast cell burden and a favorable prognosis, and are now-a-
days classified as isolated BM mastocytosis [2-5]. 
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In AdvSM prognostication is of utmost clinical importance. Thus, we analyzed the prognostic 
impact of potential prognostic factors in this group separately. Again, age turned out to be of 
prognostic importance. Other prognostic parameters were elevated tryptase, abnormal blood 
counts, and absence of skin-involvement. Using these variables, high-risk AdvSM patients were 
split into four groups, AdvSM-1, AdvSM-2, AdvSM-3, and AdvSM-4, with significant 
differences regarding OS, EFS and PFS. An interesting observation was that the prognosis of 
int-1 risk and int-2 risk patients overlaps with that found in patients with AdvSM-1. This 
observation supports the strengths and impact of the IPSM. Thus the IPSM may identify 
patients with a higher risk than expected by the WHO classification.  
The importance of prognostic variables in SM has been discussed in previous studies. Likewise, 
an elevated ß2-microglobulin, multi-lineage involvement of leukocytes with KIT D816V, the 
KIT D816V allele burden, and mutations in additional genes were reported to be of prognostic 
significance in SM [6,16,17,35]. In the current study, molecular markers were only available in 
a small subset of patients collected in the ECNM registry which shows that their use is still 
restricted to relatively few specialized centers. Moreover, molecular abnormalities are 
preferentially detected in patients who have advanced SM, such as SM-AHN. In the IPSM we 
included prognostic parameters that are of major (and independent) prognostic impact and are 
easily accessible in daily practice. In this regard it should be emphasized that in patients with 
non-AdvM, our score is based on only two basic risk-factors (age and AP), but is robust in that 
the physician can readily detect patients who have a poor prognosis, similar to the risk and 
outcome in patients with AdvSM. These non-AdvM patients need to be monitored closely (as 
patients with AdvSM) to detect progression and to define the optimal time of intervention. 
In the light of novel therapeutic options, our score may also support treatment decisions in SM. 
Patients with AdvSM usually require cytoreductive therapy and the optimal way of treatment 
depends on patient-related factors, disease aggressiveness, and the presence of an AHN 
[5,36,37]. At present therapeutic options for slowly progressing AdvSM include (off-label) 
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interferon-alpha, cladribine, and midostaurin which was approved for use in AdvSM in 2017 
[5,36-39]. By contrast, in AdvSM with rapid progression or MCL, poly-chemotherapy is often 
considered, and if possible, hematopoietic stem cell transplantation (HSCT) is performed [32-
37]. However, the curative potential of this therapy has to be weighed against side effects [5,36-
40]. For example, in older patients with slowly progressing AdvSM with low risk IPSM, 
therapy with midostaurin or cladribine may be a reasonable option [5,36]. 
In summary, the WHO classification remains an important basic prognostication tool in 
mastocytosis. However, age and AP in non-advanced SM, and age, tryptase, blood counts and 
skin involvement in AdvSM, are also of prognostic significance. By applying the related new 
score, the IPSM, prognostication in mastocytosis may improve substantially and should thus 
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Legends to Figures 
 
Figure 1 
Survival probability in different WHO subgroups of mastocytosis  
The probability of overall survival, OS (A) and progression-free survival, PFS (B) in subgroups 
of mastocytosis defined by WHO criteria was calculated according the method of Kaplan and 
Meier. Mast cell leukemia (MCL), the most aggressive mast cell disorder where progression to 
a higher disease state is not possible and mastocytosis in the skin (MIS), a provisional diagnosis 
in patients with proven skin involvement but unknown/unavailable bone marrow, were 
excluded from PFS analysis. Differences in OS and PFS between the WHO groups were 
statistically significant as assessed by log rank test (p<0.005). As visible, patients with non-
advanced mastocytosis i.e. cutaneous mastocytosis (CM), MIS, indolent systemic mastocytosis 
(ISM) and smoldering SM (SSM) have a much better prognosis compared to patients with 
advanced SM, namely aggressive SM (ASM), MCL, mast cell sarcoma (MCS) and SM with an 
associated hematologic neoplasia (SM-AHN). OS and PSF in individual AHN subgroups of 
SM-AHN are shown in Supplementary Figures 5. 
 
Figure 2 
Overall survival (OS) and progression-free survival (PFS) of patients with mastocytosis 
according to the international prognostic scoring system for mastocytosis (IPSM) 
OS was determined in all patients in whom the score could be calculated. Mast cell leukemia, 
the most aggressive mast cell disorder (cannot progress into a more aggressive variant) and 
mastocytosis in the skin (MIS), a provisional diagnosis for patients with proven skin 
involvement but unknown/unavailable bone marrow results, were excluded from analysis of 
PFS. A, B: OS (A) and PFS (B) were estimated according to the method of Kaplan and Meier. 
In these analyses, patients with Low, Intermediate (Int)-1, and Int-2 risk groups differed 
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significantly in their OS and PFS and had a favourable outcome compared to patients with 
advanced systemic mastocytosis (AdvSM) according to log rank test (p<0.005). C, D: 
Estimated OS (C) and PFS (D) according to the IPSM for patients with AdvSM. OS and PFS 
differed significantly between the cohort without risk factors (AdvSM-1), patients with one risk 
factor (AdvSM-2), those with two to three risk factors (AdvSM-3), and those with four to five 
risk factors (AdvSM-4) (p<0.0005). The OS of patients in the risk groups AdvSM-1 and 
AdvSM-2 were similar to that of non-advanced mastocytosis patients in the Int-1 and Int-2 risk 





Evolution patterns and numbers of progression events in patients with mastocytosis 











from to  
CM MPCM ISM 6 5.2 6 (6.8) 
ISM ISM SSM 12 5.5 
39 (44.3) 
 
ISM ASM 9 3.0 
 ISM MCS 1 7.9  
ISM SM-AHN1 17 1.9 
SSM SSM ASM 4 4.6 
5 (5.7)  
SSM SM-AHN2 1 0.7 
ASM ASM MCL 5 1.8 
11 (12.5)  
ASM SM-AHN3 6 1.3 
SM-AHN ISM-AHN ASM-AHN 3 2.3 
27 (30.7) 
 
ASM-AHN MCL-AHN 7 1.2 
 ASM-CMML MCL-AML 1 2.8  
SM-CEL4 SM-AML 1 1.0  
SM-MPN5 SM-AML 4 2.4  
SM-CMML6 SM-AML 4 2.2 
 SM-MDS/MPN7 SM-AML 2 1.6 
 SM-MDS8 SM-AML 5 1.0 
All patients    2.2 88 (100) 
Disease evolution was examined by analyzing progression-related events defined by a 
shift from a known disease category in a higher-graded (more advanced) form of 
mastocytosis or AHN during follow up. Abbreviations: AML, acute myeloid leukemia, 
ASM, aggressive systemic mastocytosis; CEL, chronic eosinophilic leukemia; CM, 
cutaneous mastocytosis; CMML, chronic myelomonocytic leukemia, ISM, indolent 
systemic mastocytosis; MCL, mast cell leukemia; MCS, mast cell sarcoma; MDS, 
myelodysplastic syndrome; MPN, myeloproliverative neoplasm; MDS/MPN, 
myelodysplastic/myeloproliferative overlap syndrome; n, number; SM-AHN, systemic 
mastocytosis with an associated hematologic neoplasm; SSM, smoldering systemic 
mastocytosis. 
1 i.e. ASM-CMML, n=3; ISM-NHL, n=3; ISM-AML, n=2; ISM-CML, n=2; ISM-MPN, 
n=2; ISM-CMML, n=1; ISM-other, n=1; SSM-CMML, n=1; SSM-other, n=2 
2 i.e. SSM-CMML 
3 i.e. ASM-AML, n=3; AML-CMML, n=2; ASM-MDS/MPN, n=1 
4 i.e. ASM-CEL, n=1 
5 i.e. ASM-MPN, n=3; MCL-MPN, n=1 
6 i.e. ASM-CMML, n=2; ISM-CMML, n=2 
7 i.e. ASM-MDS/MPN, n=2 














Non-advanced systemic mastocytosis Advanced systemic mastocytosis 
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
   HR 95% CI p value HR 95% CI 
p 
value 
HR 95% CI 
p 
value 
HR 95% CI p value 
Male sex 1794 - 1.80 1.02-3.15 0.041   n.s. 1.76 1.21-2.55 0.003   n.s. 
Age (years) 1794 ≥60 1.11 1.08-1.14 <0.001 12.66 6.10-26.29 <0.001 1.04 1.02-1.05 <0.001 2.05 1.37-3.06 <0.001 
Tryptase (ng/mL) 1625 ≥125 3.27 1.76-6.06 <0.001   n.s. 1.66 1.19-2.32 0.003 1.91 1.26-2.89 0.030 
Leukocytes (x109/L) 1609 ≥16 2.23 0.28-17.50 0.445   - 1.83 1.14-2.93 0.012 1.88 1.26-2.77 <0.001 
Hb (g/dL) 1618 <11.0 0.01 0.00-1.03 0.051   - 0.01 0.00-0.03 <0.001 1.71 1.12-2.60 <0.001 
PLT (x109/L) 1608 <100 0.05 0.01-0.20 <0.001   n.s. 0.17 0.11-0.26 <0.001 1.62 1.26-2.34 0.010 
LDH (U/L) 1250 ≥250 0.47 0.04-5.15 0.535   - 2.67 1.36-5.25 0.007   n.s. 
AP (U/L) 1332 ≥100 8.48 2.58-27.85 <0.001 34.71 3.93-306.50 <0.001 2.32 1.45-3.70 <0.001   n.s. 
Ca (mg/dL) 1241 ≤8.9 0.01 0.00-0.01 <0.001   n.s. 0.01 0.00-0.01 <0.001   n.s. 
Neutrophils (%) 1528 ≥50 14.69 1.08-198.77 0.043   n.s. 0.65 0.29-1.43 0.281   - 
Monocytes (%) 1493 ≥8.7 12.16 0.14-1035.14 0.271   - 3.35 1.10-10.19 0.033   n.s. 
Eosinophils (%) 1493 - 0.56 0.01-31.74 0.777   - 1.03 0.45-2.36 0.936   - 
Skin involvement 1794 - 0.95 0.44-2.04 0.895   - 0.46 0.32-0.67 <0.001 0.45 0.30-0.67 <0.001 
Organomegaly*  1655 - 3.09 1.60-5.98 <0.001   n.s. 1.15 0.76-1.72 0.513   n.s. 
Mediator symptoms  1792 - 0.77 0.42-1.40 0.389   - 0.58 0.41-0.82 0.002   n.s. 
Allergy (y/n) 1502 - 0.78 0.41-1.50 0.454   - 0.41 0.21-0.81 0.010   n.s. 
Prognostic variables were examined for their statistical power and independence from each other and from the WHO classification by uni- and multivariate analysis. AP, alkaline phosphatase; Ca, 
calcium; CI, confidence interval; CM, cutaneous mastocytosis; Eosinophils, eosinophil granulocytes; Hb, hemoglobin; HR, hazard ratio; LDH, lactate dehydrogenases; n.s., not significant and 
excluded in stepwise Cox regression; PLT, platelets; *Organomegaly i.e. enlarged spleen and/or enlarged liver and/or enlarged lymph nodes 
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